Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.47 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392667 | 0.96 | SLC6A4 (0.52) | SLC6A4ADRA1DCCR2 | |
| SCHEMBL5380517 | 0.93 | HTR1F (0.48) | SLC6A4ADRA1DCCR2HTR1F | |
| SCHEMBL5384995 | 0.87 | CCR2 (0.51) | HTR4ADRA1DCCR2 | |
| SCHEMBL8879463 | 0.85 | SLC6A4 (0.62) | SLC6A4ADRA1D | |
| SCHEMBL5396156 | 0.84 | CCR2 (0.52) | SLC6A4ADRA1DCCR2 | |
| SCHEMBL5399661 | 0.83 | CCR2 (0.53) | SLC6A4ADRA1DCCR2 | |
| SCHEMBL5392366 | 0.83 | ADRA1D (0.51) | SLC6A4ADRA1DHTR1F | |
| SCHEMBL8878576 | 0.83 | SLC6A4 (0.55) | SLC6A4ADRA1D | |
| SCHEMBL5389421 | 0.81 | ALDH1A1 (0.47) | ADRA1D | |
| SCHEMBL5389620 | 0.80 | CCR2 (0.48) | ADRA1DCCR2HTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415737-C | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2008-09-03 | — | — | CN | disclosed |
| US-7276508-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2007-10-02 | — | — | US | disclosed |
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | disclosed |
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | disclosed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | disclosed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | disclosed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | HTR4, TPH1, SLC6A3 | HTR4 1/4885SLC6A4 4/4885ADRA1D 84/4885 |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | TPH1, CHRM1, TPH2 | HTR4 12/4885SLC6A4 26/4885ADRA1D 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.